Read the Latest News

New Report on Temporomandibular Disorders: Priorities for Research and Care

Over a year and half ago, the National Academy of Medicine (NAM) began the most comprehensive study ever undertaken on Temporomandibular Disorders (TMD). The study assessed the current state of TMD research, education and training, the safety and efficacy of clinical treatments, and associated burden and costs.

Statement by NIDCR Acting Director on the National Academies of Sciences, Engineering, and Medicine Report on Temporomandibular Joint Disorders

I am pleased to announce the release of the National Academies of Sciences, Engineering, and Medicine (NASEM) report, Temporomandibular Disorders: Priorities for Research and Care. As underscored by the comprehensive report, temporomandibular joint disorders (TMJDs) are a diverse and still poorly understood set of complex, painful conditions affecting the jaw muscles and tissues, temporomandibular joints, and associated nerves. Clearly, there is much more to be understood, and these conditions continue to confound medical and dental health care providers and researchers.

Have you seen the film Dark Waters?

The Film. Dark Waters is about attorney Robert Billott's real-life 20 year legal battle against DuPont chemical for releasing toxic waste - perfluorooctanoic acid, or PFOA - into Parkersburg, West Virginia's water supply, with devastating health effects on the townspeople and livestock. PFOA, also known as C8, is a man-made chemical. It is used in the process of making Teflon and similar chemicals known as fluorotelomers.

Online TMD Diet Diary Research Project

Online TMD Diet Diary Research Project The TMJ Association received the following request from Professor Justin Durham and his research team at Newcastle University. We encourage TMJ patients to participate in this project as it is an under researched

Drug Induced Bruxism

The authors of this article state that orofacial movement disorders (bruxism) are treated typically by dental professionals and not by those specialists (neurologists) researching and treating the other movement disorders (Parkinson's disease, Huntington's disease, tremors, etc.). Again, this is more evidence of the complexity of TMD and the need for multidisciplinary research and treatment in TMD.

NIDCR Funds Consortium for Developing Dental and Orofacial Tissue Regeneration Therapies

  • May 31, 2017

The National Institute of Dental and Craniofacial Research (NIDCR) announced two new cooperative agreements aimed at developing resources and strategies for regenerating dental, oral, and craniofacial (DOC) tissues that have been damaged by disease or injury. Totaling $24 million over three years, these awards support the development of two Resource Centers as part of the NIDCR's Dental, Oral, and Craniofacial Tissue Regeneration Consortium (DOCTRC), an initiative designed to shepherd new therapies through pre-clinical studies and into human clinical trials. The ultimate goal is to develop strategies and devices that could help repair or regenerate damaged DOC tissues, including craniofacial bone, muscle and blood vessels, nerves, teeth, and salivary glands.

"By establishing this research consortium, NIDCR seeks to lead national efforts to accelerate the translation of promising DOC regenerative medicine therapies into the clinic," said NIDCR Director Martha J. Somerman, D.D.S., Ph.D. "DOCTRC is designed as a model for optimizing translation of scientific advances in this field."

To date, few DOC therapies based on regenerative medicine have been commercialized and reached the clinic. A careful analysis of NIDCR's research portfolio identified barriers to the process, and the DOCTRC was established to address them and build on the strength of existing research, using approaches such as:

  • Enhanced focus on clinical needs and involvement of practicing clinicians to inform the design of new therapies.
  • Development of approaches to generate multi-tissue composites rather than using a single tissue type.
  • Targeted translational research and early regulatory guidance.
  • Coordination among investigators and industry to develop, validate, and commercialize new tools and technologies.

DOCTRC is composed of three Stages. Stage 1, a one-year planning phase, was successfully completed in 2016. Among proposals submitted for Stage 2, two groups received awards to develop the Resource Centers over the next three years. The Centers will bring together clinical, scientific, industrial, and regulatory experts to develop an infrastructure to deliver high-quality support to Interdisciplinary Translational Projects to be launched during Stages 2 and 3. This support will entail development of standard assays, procedures, and study models to ensure that investigators can uniformly and reliably validate the technologies.

In Stage 3, the Resource Centers will collaborate with both internal and external investigators to move projects to the point of filing Investigational New Drug or Investigational Device Exemption (IND/IDE) applications with the U.S. Food and Drug Administration and launching human clinical trials.

"The DOCTRC consortium aims to streamline translation of dental, oral, and craniofacial regenerative therapies by leveraging multidisciplinary expertise to establish a systematic and uniform research process," said Nadya Lumelsky, Ph.D., Program Director of NIDCR's Tissue Engineering and Regenerative Medicine Research Program. "By establishing two national cores to support the regenerative medicine research community, DOCTRC represents a new paradigm in translational medicine."

The following RCs will be funded for up to three years:

Additional articles related to this announcement:
School of Dentistry Leads Major New Regenerative Medicine Center Funded by NIH

UCSF to Lead Resource Team for Craniofacial, Oral and Dental Tissue Regeneration

TMJ Disorders


Login or Register to add Comment